Picture of CDT Equity logo

CDT CDT Equity Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-26.88%
3m-74.08%
6m-93.66%
1yr-99.41%
Volume Change (%)
10d/3m-77.38%
Price vs... (%)
52w High-99.4%
50d MA-26.47%
200d MA-96.43%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-594.05%
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of CDT Equity EPS forecast chart

Profile Summary

CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    March 31st, 2025
    Incorporated
    October 19th, 2021
    Public Since
    February 3rd, 2022
    No. of Shareholders
    400
    No. of Employees
    6
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    3,062,025

    CDT Share Price Performance

    Similar to CDT

    Picture of ABVC Biopharma logo

    ABVC Biopharma

    us flag iconNASDAQ Capital Market

    Picture of Acesis Holdings logo

    Acesis Holdings

    us flag iconNASDAQ Capital Market

    Picture of Achieve Life Sciences logo

    Achieve Life Sciences

    us flag iconNASDAQ Capital Market

    Picture of Aclarion logo

    Aclarion

    us flag iconNASDAQ Capital Market

    Picture of Acurx Pharmaceuticals logo

    Acurx Pharmaceuticals

    us flag iconNASDAQ Capital Market

    FAQ